Clinical Trials Logo

Clinical Trial Summary

To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.


Clinical Trial Description

Primary Objective To determine the effect of olanzapine on opioid craving among patients receiving opioids for cancer pain (Opioid Craving Scale; Opioid Craving Visual Analogue Scale, change from baseline) Secondary Objective To determine the effect of olanzapine on opioid misuse among patients receiving opioids for cancer pain (Current Opioid Misuse Measure, change from baseline) Exploratory Objective - To estimate the effect of olanzapine and placebo on the amount of opioid use among patients receiving opioids for cancer pain (morphine equivalent daily dose) - To determine the effect of olanzapine and placebo on pain intensity among patients receiving opioids for cancer pain (Brief Pain Inventory) - To determine the effect of olanzapine and placebo on overall symptom burden among patients receiving opioids for cancer pain (ESAS symptom Distress Score) - To estimate the differences between the olanzapine and placebo effects on opioid craving and misuse measures (Opioid Craving Scale, Opioid Craving Visual Analogue Scale, Current Opioid Misuse Measure) - To determine the adverse effects of olanzapine and placebo among patients receiving opioids for cancer pain (National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06200181
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Joseph Arthur, MD
Phone (713) 794-1649
Email jaarthur@mdanderson.org
Status Recruiting
Phase Phase 3
Start date April 2, 2024
Completion date November 1, 2026